This star-studded appeal continues to build public support for groundbreaking translational research, supported through SU2C programs, that can provide patients with new therapies to save lives now. SU2C brings together scientists from different disciplines across institutions and international boundaries to collaborate on finding new treatments that can account for more than 80 percent of all cancer diagnoses in the U.S. and Canada.

The first four SU2C telecasts took place on September 5, 2008, September 10, 2010, September 7, 2012, and September 5, 2014, and were made available to more than 190 countries. The first Canadian-inclusive SU2C telecast aired in 2014, and this year’s show will again air across all four major English-language Canadian broadcasters: CBC, City, CTV, and Global. Additionally, Canadian services AMI, Bloomberg TV Canada, CHCH, CHEK, Fight Network, Hollywood Suite, Joytv, NTV and TLN will also air the telecast, and it will be available on-demand on shomi and TELUS Optik TV in Canada.


SU2C is a major force in the development of innovative and more effective cancer treatments such as immunotherapy, which empowers the body’s own immune system to fight cancer cells. SU2C is supporting advancements in immunotherapy treatments for leukemia, melanoma, and cancers of the pancreas, head and neck, lung, and ovary. SU2C also supports development of precision therapies tailored to the patient's specific genetic and molecular makeup in prostate and colorectal cancers and melanoma, among others; new technology to accelerate research; early detection of colorectal cancer; prevention of ovarian cancer; and groundbreaking work on cancer stem cells and the epigenetics (processes that control so-called “packaging” of DNA) of cancer, among other new fields.

To date, more than $370 million has been pledged to support SU2C’s innovative model of collaborative cancer research. Since launching in 2008, Stand Up To Cancer has brought together more than 1,200 of the best and the brightest research scientists from more than 140 leading institutions in seven countries to fund 19 “Dream Teams,” and six translational research teams; as well as 36 early-career, innovative scientists carrying out high-risk, potentially high-reward projects. The research is aimed at ending cancer’s reign as a leading cause of death worldwide. SU2C-funded researchers have planned, launched or completed more than 160 clinical trials involving over 9,000 patients. Work by SU2C-supported researchers has led to FDA approval of two new treatments.

Rad Oncology Homepage